Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks
Bharathi S. Gadad, Manish K. Jha, Andrew H. Czysz, et al.
Journal of Affective Disorders (2017) Vol. 233, pp. 3-14
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review
Yena Lee, Renee‐Marie Ragguett, Rodrigo B. Mansur, et al.
Journal of Affective Disorders (2018) Vol. 241, pp. 519-532
Closed Access | Times Cited: 353
Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls
Mariska Bot, Yuri Milaneschi, Tahani Alshehri, et al.
Biological Psychiatry (2019) Vol. 87, Iss. 5, pp. 409-418
Open Access | Times Cited: 188
Bipolar depression: a major unsolved challenge
Ross J. Baldessarini, Gustavo Vázquez, Leonardo Tondo
International Journal of Bipolar Disorders (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 183
Exosomes from patients with major depression cause depressive-like behaviors in mice with involvement of miR-139-5p-regulated neurogenesis
Ze‐Xu Wei, Guojun Xie, Xiao Mao, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 6, pp. 1050-1058
Open Access | Times Cited: 174
Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study
Junxi Pan, Jinjun Xia, Feng-Li Deng, et al.
Translational Psychiatry (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 171
Peripheral Markers of Depression
Aleksander Nobis, Daniel Zalewski, Napoleon Waszkiewicz
Journal of Clinical Medicine (2020) Vol. 9, Iss. 12, pp. 3793-3793
Open Access | Times Cited: 146
Inflammatory profiles of severe treatment-resistant depression
Rebecca Strawbridge, John Hodsoll, Timothy R. Powell, et al.
Journal of Affective Disorders (2018) Vol. 246, pp. 42-51
Open Access | Times Cited: 103
Biomarkers of Post-COVID Depression
Piotr Lorkiewicz, Napoleon Waszkiewicz
Journal of Clinical Medicine (2021) Vol. 10, Iss. 18, pp. 4142-4142
Open Access | Times Cited: 92
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
Siamak MahmoudianDehkordi, Ahmed T. Ahmed, Sudeepa Bhattacharyya, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 71
Postpartum Depression: Current Status and Possible Identification Using Biomarkers
Yi Yu, Hong-Feng Liang, Jing Chen, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 68
Targeting neuroinflammation by polyphenols: A promising therapeutic approach against inflammation-associated depression
Mohammed Abu Tayab, Mohammad Nazmul Islam, Kazi Ashfak Ahmed Chowdhury, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112668-112668
Open Access | Times Cited: 65
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
Gustavo C. Medeiros, Todd D. Gould, William L. Prueitt, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 9, pp. 3658-3669
Open Access | Times Cited: 40
Major depressive disorder: Biomarkers and biosensors
Masoomeh Dadkhah, Mohsen Jafarzadehgharehziaaddin, Soheila Molaei, et al.
Clinica Chimica Acta (2023) Vol. 547, pp. 117437-117437
Closed Access | Times Cited: 24
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Alice Lineham, Victor J. Avila‐Quintero, Michael H. Bloch, et al.
Journal of Child and Adolescent Psychopharmacology (2024) Vol. 34, Iss. 2, pp. 73-79
Closed Access | Times Cited: 10
Apple polyphenol extract ameliorates sugary-diet-induced depression-like behaviors in male C57BL/6 mice by inhibiting the inflammation of the gut–brain axis
Yisha Xie, Zhengli Wu, Qingfan Qian, et al.
Food & Function (2024) Vol. 15, Iss. 6, pp. 2939-2959
Closed Access | Times Cited: 10
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
Roger S. McIntyre, Rakesh Jain
CNS Drugs (2024) Vol. 38, Iss. 11, pp. 869-890
Open Access | Times Cited: 10
Exploring the combined effects of serum tumor necrosis factor-alpha and serotonin on antidepressant efficacy in depression: A 12-week prospective analysis
Jae‐Min Kim, Hee‐Ju Kang, Ju‐Wan Kim, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111328-111328
Closed Access | Times Cited: 1
Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective
Kenji Hashimoto
Advances in clinical chemistry (2018), pp. 81-99
Closed Access | Times Cited: 70
Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial
Zhiyong Cao, Yun‐Zi Liu, Jiamei Li, et al.
Journal of Affective Disorders (2020) Vol. 265, pp. 247-254
Closed Access | Times Cited: 68
Magnolol abrogates chronic mild stress-induced depressive-like behaviors by inhibiting neuroinflammation and oxidative stress in the prefrontal cortex of mice
Jie Cheng, Shuqi Dong, Li‐Tao Yi, et al.
International Immunopharmacology (2018) Vol. 59, pp. 61-67
Closed Access | Times Cited: 67
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies
Lucia Carboni, Dennis J. McCarthy, Bruno Delafont, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 65
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Sudeepa Bhattacharyya, Ahmed T. Ahmed, Matthias Arnold, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 64
Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis
Hisayuki Erabi, Go Okada, Chiyo Shibasaki, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 64
Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art
E. Van Assche, Josep Antoni Ramos‐Quiroga, Carmine M. Pariante, et al.
European Neuropsychopharmacology (2022) Vol. 60, pp. 100-116
Open Access | Times Cited: 37
The role and mechanism of tryptophan – kynurenine metabolic pathway in depression
Xiaoli Gong, Rui Chang, Ju Zou, et al.
Reviews in the Neurosciences (2022) Vol. 34, Iss. 3, pp. 313-324
Closed Access | Times Cited: 35
Page 1 - Next Page

Scroll to top